Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2020-11-20
2023-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although there are many epidemiological studies highlighting the interconnections between COPD and lung cancer and the influence of cigarette smoke, the molecular bases of this association are less well defined. Initially they were thought to be driven just by innate inflammation, however, recent studies have also demonstrated the influence of the adaptive immune system. Despite this, the role of immune checkpoints in chronic lung inflammatory diseases such as COPD is less well understood. COPD is currently the 4th leading cause of death worldwide but is assessed to be the 3rd by the end of 2020 resulting in an economic and social burden that is in continuous progression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Chronic Obstructive Pulmonary Disease
NCT04963023
Biomarkers for Diagnosis and Treatment of COPD
NCT02633280
Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study
NCT02076061
Innate Immunity in COPD
NCT05743582
Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD
NCT03274791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Although there are many epidemiological studies highlighting the interconnections between COPD and lung cancer and the influence of cigarette smoke, the molecular bases of this association are less well defined. Initially they were thought to be driven just by innate inflammation, however, recent studies have also demonstrated the influence of the adaptive immune system. Despite this, the role of immune checkpoints in chronic lung inflammatory diseases such as COPD is less well understood. COPD is currently the 4th leading cause of death worldwide but is assessed to be the 3rd by the end of 2020 resulting in an economic and social burden that is in continuous progression.
Patients will be recruited from from the outpatient clinics of the Pulmonary and Critical Care Medicine department of "Mauro Scarlato" Hospital in Scafati, Italy in collaboration with the Operational Unit of Clinical Pharmacology and Pharmacovigilance of Catanzaro University.
171 patients will be divided according to the results of the anatomopathological examinations into four groups:
* Healthy never smokers
* Smokers with normal lung
* Cancer
* COPD (COPD group was divided in two subgroups: GOLD 1-2 group and GOLD 3-4 group).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy never smokers
Clinical evaluation of immune check points expression. A prospective study
check immune check points
we will evaluate the expression of immune check points
Smokers with normal lung function
evaluation of immune check points expression
check immune check points
we will evaluate the expression of immune check points
Lung cancer
evaluation of immune check points expression
check immune check points
we will evaluate the expression of immune check points
COPD
evaluation of immune check points expression
check immune check points
we will evaluate the expression of immune check points
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
check immune check points
we will evaluate the expression of immune check points
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed the informed consent
* subjects on glucocorticoid therapy
* alcohol consumption (\>3 alcoholic beverages daily)
* substance abuse
* inability to give written informed consent
* those who will not sign the consent to the processing of personal data
Exclusion Criteria
* interstitiopathy
* asthma,
* autoimmune diseases,
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Sanitaria Provinciale Di Catanzaro
OTHER
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
OTHER
University of Catanzaro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luca Gallelli
Principal Investigator, Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Luca Gallelli
Catanzaro, CZ, Italy
AO Materdomini
Catanzaro, Italia, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
361/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.